The Oxford company is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity.
Accession Therapeutics has raised €19M across 1 funding round from 3 investors, most recently a round in Nov 2022. Based in Oxford, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-28 | Other |
| €19M |
| Birk Venture,iGlobe Partners,Primavera Venture Partners |
| View deal → |
